Privately held Scil Proteins GmbH, of Halle, Germany, has concluded a financing round with BioNet Holding GmbH, worth €24 million ($33.1 million). The funds will be used to move two preclinical products derived from Scil Proteins' Affilin scaffold technology platform into Phase I studies over the next three years.